In patients with heart failure with reduced ejection fraction, which mineralocorticoid receptor antagonist—spironolactone, eplerenone, or finerenone—is preferred?

Spironolactone or Eplerenone for HFrEF

For patients with heart failure with reduced ejection fraction (HFrEF), both spironolactone and eplerenone are equally recommended as first-line mineralocorticoid receptor antagonists (MRAs) with proven mortality and morbidity benefits, while finerenone is not currently indicated for HFrEF. 1

Guideline-Based Recommendation

The 2022 AHA/ACC/HFSA guidelines provide a Class 1, Level A recommendation for either spironolactone or eplerenone in HFrEF patients with NYHA class II-IV symptoms, provided eGFR is >30 mL/min/1.73 m² and serum potassium is <5.0 mEq/L 1. The guidelines explicitly state both agents reduce morbidity and mortality, and both are considered high economic value therapies 1.

The evidence base includes:

• RALES trial (spironolactone): Enrolled highly symptomatic patients with LVEF ≤35%
• EPHESUS trial (eplerenone): Post-MI patients with LVEF ≤40%
• EMPHASIS-HF trial (eplerenone): Mild symptoms with LVEF ≤30%

All three landmark trials demonstrated significant benefit 1.

Choosing Between Spironolactone and Eplerenone

Efficacy Comparison

Eplerenone demonstrates superior all-cause mortality reduction compared to spironolactone (HR=0.78,95% CI [0.66,0.91]) with moderate-quality evidence 2. However, spironolactone shows better performance in preventing hospitalizations:

• Composite cardiovascular death or hospitalization: HR=0.67 (95% CI [0.50,0.89]) 2
• HF hospitalization: HR=0.61 (95% CI [0.43,0.86]) 2
• All-cause hospitalization: HR=0.51 (95% CI [0.26,0.98]) 2

The most recent individual patient-level meta-analysis (2024) found both steroidal MRAs reduce cardiovascular death or HF hospitalization in HFrEF (HR 0.66,95% CI 0.59-0.73), with significant reductions in HF hospitalization and cardiovascular death 3.

Safety Profile: The Critical Differentiator

Eplerenone has a superior safety profile compared to spironolactone 2. This is clinically significant because:

• Eplerenone is a selective MRA with minimal anti-androgen effects
• Spironolactone causes gynecomastia, breast tenderness, and sexual dysfunction due to non-selective steroid receptor binding
• Both carry hyperkalemia risk (doubled compared to placebo, OR 2.27), but serious hyperkalemia (K+ >6.0 mEq/L) remains low at 2.9% vs 1.4% with placebo 3

Practical Algorithm for Selection

Start with eplerenone if:

• Patient is male (to avoid gynecomastia)
• Patient has concerns about sexual side effects
• Cost is not prohibitive
• Primary goal is mortality reduction

Start with spironolactone if:

• Cost is a major barrier (generic spironolactone is significantly cheaper)
• Primary goal is reducing hospitalizations
• Patient has no concerns about endocrine side effects
• Patient is female (lower risk of bothersome side effects)

Dosing Strategy

Eplerenone 4:

• Start: 25 mg once daily
• Target: 50 mg once daily within 4 weeks
• Adjust based on potassium levels (hold if K+ ≥6.0 mEq/L)

Spironolactone 1:

• Start: 25 mg once daily
• Target: 50 mg once daily after one month
• Reduce dose by half if eGFR 31-49 mL/min/1.73 m²

What About Finerenone?

Finerenone is NOT indicated for HFrEF. The FDA approval for finerenone is limited to:

1. Heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) 3, 5
2. Chronic kidney disease with type 2 diabetes 6, 5

While finerenone shows the best safety profile among all MRAs (lowest rates of hyperkalemia, renal injury, and adverse events) 2, it has not been studied in HFrEF populations and should not be used for this indication.

Monitoring Requirements

Critical monitoring protocol (applies to both agents) 1:

• Check potassium and renal function at 1 week, then 4 weeks, then every 6 months
• More frequent monitoring during clinical instability
• Discontinue if potassium cannot be maintained <5.5 mEq/L (Class 3: Harm recommendation) 1

Common Pitfalls to Avoid

1. Underutilization: MRAs remain underused despite Class 1 evidence; don't delay initiation in eligible patients
2. Premature discontinuation: Don't stop due to mild hyperkalemia (K+ 5.0-5.4 mEq/L); adjust dose instead 4
3. Wrong agent selection: Don't use finerenone for HFrEF—it lacks evidence in this population
4. Inadequate monitoring: Hyperkalemia risk is real but manageable with proper surveillance
5. Cost barriers: If eplerenone is unaffordable, use spironolactone rather than no MRA at all